

## Alirocumab Biosimilar - Research Grade ICH4016

### Product Information

<b>Catalog Number:</b>	ICH4016
<b>Product:</b>	Low endotoxin, biosimilar antibody
<b>Target:</b>	PCSK9
<b>Isotype:</b>	IgG1
<b>Other names:</b>	Proprotein convertase subtilisin/kexin type 9, NARC-1, PC9
<b>Host:</b>	Humanized
<b>Species Reactivity:</b>	Human
<b>Specificity:</b>	Detects human PCSK9. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Alirocumab.
<b>Purification method:</b>	This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
<b>Concentration:</b>	1.0 - 5.0 mg/ml
<b>Formulation:</b>	Phosphate buffered saline (PBS) pH 7.2, with no carrier protein, potassium or preservatives added. BSA and Azide free.
<b>Purity:</b>	>95% by SDS-PAGE and HPLC
<b>Endotoxin:</b>	≤ 0.75 EU/mg as determined by the LAL method
<b>Storage:</b>	Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

### Background:

Alirocumab biosimilar is a human monoclonal antibody (IgG1 isotype) that targets proprotein convertase subtilisin kexin type 9 (PCSK9), is a PCSK9 inhibitor produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Alirocumab biosimilar consists of two disulfide-linked human heavy chains, each covalently linked through a disulfide bond to a human kappa light chain. A single Nlinked glycosylation site is located in each heavy chain within the CH2 domain of the Fc constant region of the molecule. The variable domains of the heavy and light chains combine to form the PCSK9 binding site within the antibody. Alirocumab biosimilar has an approximate molecular weight of 146 kDa.